Eletriptan

Expert Opinion on Investigational Drugs

Volumn 10, Issue 10, 2001, Pages 1869-1874

  Grujich, N N ^a   Gawel, M J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute therapy; Eletriptan; Headache; Migraine; Symptomatic treatment; Triptans

Indexed keywords

ANTIMIGRAINE AGENT; ELETRIPTAN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN;

ADVERSE DRUG REACTION; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; NAUSEA; PARESTHESIA; PATIENT ATTITUDE; SYMPTOM;

CLINICAL TRIALS; HUMANS; INDOLES; MIGRAINE DISORDERS; PYRROLIDINES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0034769383     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.10.1869     Document Type: Article

References (34)

1. Inhibition of trigeminal neurons after intravenous administration of naratriptan through an action at 5-hydroxytryptamine (5-HT1B/1D) receptors
2. Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses
3. Neurogenic versus vascular response of sumatriptan and ergot alkaloids in migraine
4. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan
5. Efficacy, safety, and tolerability of oral eletriptan (40 mg and 80 mg) in the acute treatment of migraine: Results of a Phase III study
6. Comparison of oral eletriptan (40-80 mg) and oral sumatriptan (50-100 mg) for the treatment of acute migraine: A randomized, placebo-controlled trial in sumatriptan-naïve patients
7. Comparison of the efficacy, safety and tolerability of oral eletriptan and Cafergot for the acute treatment of migraine
8. In vitro metabolism of eletriptan in human liver microsomes
9. Migraine pharmacotherapy with oral triptans: A rational approach to clinical management
10. The relevance of hepatic intrinsic clearance and brain penetration on the doses used for 5-HT1B/1D agonists (triptans) in the treatment of migraine
11. 1D receptor agonist
12. Rational migraine management: Optimizing treatment with the triptans
13. 3H]eletriptan binding at human 5-HT1b and 5-HT1D receptors
14. Characterisation of the contractile activity of eletriptan at the canine vascular 5-HT1B receptor
15. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels
16. Pharmacological analysis of contraction to eletriptan in the human isolated middle meningeal artery
17. Absorption of effervescent aspirin during migraine
18. Further characterization of the in vitro pharmacology of eletriptan
19. 1B/1D - Receptor agonist
20. Oral sumatriptan in pharmacokinetics in migrainous state
21. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in migraine-free period
22. The absorption kinetics of eletriptan in migraineurs
23. A comparison of oral eletriptan (UK-116,044) (20-80 mg) and oral sumatriptan (100mg) in the acute treatment of migraine
24. A dose-finding study of eletriptan (UK-116,044) (5-30 mg) for the acute treatment of migraine
25. Headache recurrence following single doses of oral eletriptan: Review of clinical trial experience
26. Treatment of headache recurrence with a second dose of oral eletriptan: Meta-analysis across Phase III clinical trials
27. Pharmacokinetics of the triptans
28. Effect of encapsulation on absorption of sumatriptan tablets: Data from healthy volunteers and patients during migraine
29. Efficacy of eletriptan for the treatment of migraine in women, in menstrually associated migraine and in women taking oral contraceptives or hormone replacement therapy: Meta-analyses of randomized clinical trials
30. Safety, tolerability and efficacy of eletriptan (40-80 mg) for the long term treatment of migraine
31. Comparison of the effectiveness or oral eletriptan (40-80 mg) and oral sumatriptan (50-100 mg) in reducing the time loss and overall impact of migraine attacks
32. Adverse event profile of oral eletriptan: Review of clinical trial experience
33. The pharmacokinetics, safety and tolerability of oral eletriptan in subjects with impaired hepatic function
34. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral eletriptan in young and elderly, male and female subjects